Repligen Reports Fourth Quarter and Full Year 2022 Financial Results

Go back to Repligen Reports Fourth Quarter and Full Year 2022 Financial Results

Repligen (RGEN) Tops Q4 EPS by 10c, Guidance Falls Short of Conensus

February 22, 2023 7:40 AM EST

Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.68, $0.10 better than the analyst estimate of $0.58. Revenue for the quarter came in at $186.8 million versus the consensus estimate of $186.3 million.

GUIDANCE:

Repligen sees FY2023 EPS of $2.61-$2.69, versus the consensus of $2.92. Repligen sees... More